Immunotherapy has had little success in PDAC. The authors report an in-depth investigation of the PDAC tumor microenvironment that highlights PD-1 and TIGIT, or their corresponding ligands, as potential targets… Click to show full abstract
Immunotherapy has had little success in PDAC. The authors report an in-depth investigation of the PDAC tumor microenvironment that highlights PD-1 and TIGIT, or their corresponding ligands, as potential targets for combinatorial therapy to treat this devastating disease.
               
Click one of the above tabs to view related content.